Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Down – Here’s Why

Posted by Brian Himes on Nov 10th, 2026

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $15.31, but opened at $14.12. Trevi Therapeutics shares last traded at $14.9010, with a volume of 293,435 shares traded.

Analysts Set New Price Targets

TRVI has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Thursday, October 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a report on Wednesday, October 7th. Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. JonesTrading upped their price objective on Trevi Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $27.08.

View Our Latest Stock Analysis on TRVI

Trevi Therapeutics Stock Down 6.5%

The company has a fifty day moving average of $14.24 and a two-hundred day moving average of $14.41. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -42.12 and a beta of 1.15.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). Equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Trevi Therapeutics

In other news, Director Michael Heffernan sold 39,473 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the transaction, the director directly owned 6,351 shares in the company, valued at $95,836.59. The trade was a 86.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 15.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Trevi Therapeutics during the 2nd quarter valued at about $208,041,000. Artia Global Partners LP purchased a new stake in shares of Trevi Therapeutics in the second quarter valued at $41,232,000. First Light Asset Management LLC purchased a new stake in shares of Trevi Therapeutics in the second quarter valued at $39,113,000. Assenagon Asset Management S.A. boosted its stake in shares of Trevi Therapeutics by 131.2% during the third quarter. Assenagon Asset Management S.A. now owns 3,527,035 shares of the company’s stock valued at $50,507,000 after acquiring an additional 2,001,721 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Trevi Therapeutics during the second quarter valued at $28,588,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

(Get Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis.

Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.

Trevi is headquartered in New Haven, Connecticut, and its operations are centered on developing its drug candidate.